EMA Withdrawn: Topotecan Teva (topotecan) — Teva B.V.

View source ↗

Summary

Topotecan Teva has been withdrawn from the market by Teva B.V., affecting indications in ovarian neoplasms, uterine cervical neoplasms, and small cell lung carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms
• Small Cell Lung Carcinoma
• Uterine Cervical Neoplasms

Drugs mentioned

• Topotecan Teva (topotecan)

Snippet

Status: Withdrawn. Therapeutic area: Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma. MAH: Teva B.V.. Decision date: 22/06/2018